Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Prior

Showing results (411-420 of 414) with videos related to

Pageof 42
Sort By:
You have reached the last page of results.This site can display upto 414 results.
Blood|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myelomaOla Landgren, Thomas J Prior, Tara Masterson, et al.
Chemical Communications (Cambridge, England)|June 9, 2020
An ethylene cross-bridged pentaazamacrocycle and its Cu<sup>2+</sup> complex: constrained ligand topology and excellent kinetic stabilityAnthony D Shircliff, Benjamin P Burke, Dustin J Davilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized TrialsQian Shi, Bruno Paiva, Levi D Pederson, et al.
Blood|September 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 studyAjai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria, et al.
Pageof 42

Showing results (411-420 of 414) with videos related to

Sort By:
Pageof 42
You have reached the last page of results.This site can display upto 414 results.
Blood|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myelomaOla Landgren, Thomas J Prior, Tara Masterson, et al.
Chemical Communications (Cambridge, England)|June 9, 2020
An ethylene cross-bridged pentaazamacrocycle and its Cu<sup>2+</sup> complex: constrained ligand topology and excellent kinetic stabilityAnthony D Shircliff, Benjamin P Burke, Dustin J Davilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized TrialsQian Shi, Bruno Paiva, Levi D Pederson, et al.
Blood|September 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 studyAjai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria, et al.
Pageof 42